Zenocutuzumab
Based on 1 publication(s) in Google Scholar
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 1969309-56-5
- Molecular Weight:145.76 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Zenocutuzumab
MoreAll EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
ERBB2/HER2/CD340
Zenocutuzumab (0.001-1000 nM; 96 hours) inhibits cell growth in lung and breast cancer cell lines[1].
Zenocutuzumab (0.1-1000 nM; 24 hours) inhibits HER3 and AKT phosphorylation, induces markers of apoptosis and cell cycle arrest in lung and breast cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human bronchiolar epithelial cell lines (HBEC)
-
Concentration:0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:96 h
-
Result:Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.
-
Cell Line:HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:24 hours
-
Result:Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1].
-
Dosage:2.5 mg/kg, 8 mg/kg, or 25 mg/kg
-
Administration:i.p.; once weekly; for 28 days
-
Result:Blocked growth of lung and ovarian cancer PDX models.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 MCF-7 cells with Zenocutuzumab (HY-P99507, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized HER2/CD340 Protein, Human (HEK293, HY-P73094) can bind Zenocutuzumab. The EC50 for this effect is 2.42 ng/mL. -
Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Zenocutuzumab. The EC50 for this effect is 31.77 ng/mL.
Chemical Information
-
CAS No. 1969309-56-5
-
Appearance Liquid
-
Molecular Weight 145.76 kDa
-
Color Colorless to light yellow
-
SMILES
[Zenocutuzumab]
-
Synonyms
MCLA-128; PB4188; R040517
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)